Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tirzepatide

Mounjaro

Bibliografia - Quali fonti bibliografiche per Tirzepatide?

  1. Abdi A. et al., J. Am. Pharm. Assoc. (2003), 2025, 1, 102474.

  2. Agenzia Italiana del Farmaco – AIFA, Mounjaro – Riassunto Caratteristica di Prodotto, 2025, 13 marzo.

  3. Aitken A.E., Morgan E.T., Drug Metab. Dispos., 2007, 35 (9), 1687.

  4. Akiska Y.M. et al., European Academy of Dermatology and Venereology (EADV) 2025 Congress, ePoster Showcase EPS01.4, 2025, 17-20 September.

  5. American Diabetes Association – ADA, Symposium disentangles perception from reality regarding potential adverse effects of GLP-1 RAs, 2024, June 24 https://www.adameetingnews.org/symposium-disentangles-perception-from-reality-regarding-potential-adverse-effects-of-glp-1-ras/ (accesso: ottobre 2025).

  6. Aronne L.J. et al., JAMA, 2024, 331 (1), 38 (studio clinico SURMONT-4).

  7. Aronne L. J. et al., NEJM, 2025, https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394 (accesso: settembre 2025).

  8. Bezin J. et al., Diabetes Care, 2023, 46 (2), 384.

  9. Caruso I. et al., J. Endocrinol. Invest., 2024, 47 (11), 2671.

  10. Chavda V.P. et al., Molecules, 2022, 27 (13), 4315.

  11. Cheymol G. et al., Clin. Pharmacokinet., 1993, 25 (2), 103.

  12. Dahl D. et al., JAMA, 2022, 327 (6), 534 (studio clinico SURPASS-5).

  13. Del Prato S. et al., Lancet, 2021, 398 (10313), 1811 (studio clinico SURPASS-4).

  14. Eli Lilly, Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease, 2025, 31 July https://investor.lilly.com/node/52671/pdf (accesso: settembre 2025)

  15. European Medicine Agency – EMA, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 23-26 October 2023 - GLP-1 receptor agonists: available evidence not supporting link with thyroid cancer, 2023, 27 October https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023 (accesso: settembre 2025).

  16. European Medicine Agency – EMA, Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 July 2024 - New recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation, 2024, 12 July https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-july-2024 (accesso: settembre 2025).

  17. Ferch M. et al., J. Clin. Endocrinol. Metab., 2025, Apr 30, dgaf258.

  18. Food and Drug Administration – FDA, Zepbound – Prescribing Information, 2025, February https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf (accesso: settembre 2025).

  19. Food and Drug Administration – FDA, Mounjaro – Prescribing Information, 2025a, May https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s031lbl.pdf

  20. Frias J.P. et al., NEJM, 2021, 385 (6), 503 (studio clinico SURPASS-2).

  21. Garvey W.T. et al., Lancet, 2023, 402, 10402, 613 (studio clinic SURMONT-2).

  22. Giorgino F. et al., Diabetes Care, 2024, 47 (6), 1020.

  23. Gong J. et al., J. Diabetes Investig. 2025, 16 (1), 83.

  24. Grennan K. et al., JCEM Case Rep., 2025, 3 (6), luaf087.

  25. Guo H. et al., Front. Pharmacol., 2024, 15, 1461398.

  26. Hall K.D., Obesity (Silver Spring), 2024, 32 (6), 1163.

  27. Hannon T.S. et al., Lancet, 2025, 406 (10511), P1484 (studio clinico SURPASS-PED).

  28. Henney A.E. et al., Ann. Am. Thorac. Soc., 2025, 22 (7), 1042.

  29. Hiber H. et al., J. Pharmacol. Exp. Ther., 2001, 297 81), 174.

  30. Jastreboff A.M. et al., NEJM, 2022, 387 (3), 205 (studio clinico SURMONT-1).

  31. Karakus K.E. et al., JAMA Intern. Med., 2024, 184 (10), 1246.

  32. Katz B.J. et al., JAMA Ophthalmol. 2025, 143 (3), 215.

  33. Kittleson M.M.et al., ACC Scietific Statements, 2025, 13 June https://www.jacc.org/doi/10.1016/j.jacc.2025.05.008 (accesso: settembre 2025).

  34. La Vignera S. et al., Reprod. Biol. Endocrinol., 2025, 23 (1), 92.

  35. LactMed, 2023, 15 November, https://www.ncbi.nlm.nih.gov/books/NBK581488/ (accesso:settembre 2025).

  36. Lenkov R. et al., Clin. Nucl. Med., 2025, Mar 19. doi: 10.1097/RLU.0000000000005856.

  37. Liddle C. et al., J. Clin. Endocrinol. Metab., 1998, 83 (7), 2411.

  38. LiverTox, Tirzepatide, 2025, June 27 https://www.ncbi.nlm.nih.gov/books/NBK581694/ (accesso: settembre 2025).

  39. Loomba R. et al., NEJM, 2024, 391 (4), 299.

  40. Ludvik B. et al., Lancet. 2021, 398 (10300), 583 (studio clinico SURPASS-3).

  41. Malhotra A. et al., NEJM, 2024, 391 (13), 1193 (studio clinico SURMONT-OSA).

  42. Mando N. et al., Cureus. 2024, 16 (12), e76007.

  43. Mavromatis L.A. et al., Diabetes Obes. Metab., 2025, 27 (8), 4571.

  44. Min J.S. et al., Drug Des. Devel. Ther., 2025, 19, 3509.

  45. Nieto L.M. et al., Am. J. Gastroenterol., 2025, May 13, doi: 10.14309/ajg.0000000000003525.

  46. Okuma H., Cureus, 2025, 17 (5), e83712.

  47. Packer M. et al., NEJM, 2025, 392 (5), 427.

  48. Portillo Canales S. et al., ENDO Annual Meeting: RF27-03, 2025, July 12-15, San Francisco.

  49. Rosenstock J. et al., 2021, Lancet, 398 (10295), 143 (studio clinico SURPASS-1).

  50. Schneck K., Urv S.a, 2024 CPT Pharmacometrics Syst. Pharmacol., 2024, 13 (3), 494.

  51. Skelley J.W. et al., J. Am. Pharm. Assoc (2003), 2024, 64 (1), 204.

  52. Snaith J.R. et al., OP 13 GLP-! Trending: the latest developments – Oral Presentation 75, 61st EASD Annual Meeting of the European Associacion for the Study of Diabetes, 2025 (studio clinic TIRTLE1).

  53. Tucker J.M., Ritchie J., J. Investig. Med. High Impact. Case Rep., 2024, Jan-Dec:12:23247096241264635.

  54. Wadden T.A. et al., Nat. Med., 2023, 29 (11), 2909 (studio clinico SURMONT-3).

  55. Wu J.Y. et al., Diabetes Res. Clin. Pract., 2025, 226, 112294.

  56. Yilmaz B. et al., Hippokratia, 2014, 18 (4), 377.